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RESUMEN 
 
 
El Papilomavirus Humano (PVH) es la infección de transmisión sexual más común 
en el mundo, el mismo que puede producir neoplasias intraepiteliales y cáncer cervical y 
en el área anogenital. La detección de la distribución de los tipos de PVH entre lesiones 
cancerosas es necesaria para analizar el potencial impacto de las vacunas disponibles y la 
implementación de estrategias profilácticas y de cribado. La identificación molecular de 
variantes de PVH es una herramienta poderosa para revelar información epidemiológica 
y filogenética sobre los genomas circulantes en un área específica. Sin embargo, en 
Ecuador, existe información limitada sobre los tipos de PVH en lesiones cancerosas y aún 
más limitada sobre sus variantes. El objetivo de este estudio fue caracterizar los tipos de 
PVH responsables de las neoplasias asociadas al tracto genital en mujeres ecuatorianas 
que asistieron a un hospital en Quito. El PVH fue tipificado mediante el 21 HPV 
GenoArray Diagnostic Kit. Un total de 167 muestras pre-cancerosas y cancerosas fueron 
analizadas y un 86% fueron PVH positivas. Los tipos más comunes fueron PVH16 (42%) 
y PVH58 (31%) en todos los grados de lesión. PVH18 estuvo presente únicamente en 4 
muestras (2.4%). Las muestras positivas para PVH16 y PVH58 fueron analizadas al 
amplificar y secuenciar los genes L1 y E6. Los resultados de estos análisis indicaron que 
14 (93%) muestras PVH16 positivas pertenecieron al linaje Europeo y únicamente 1 (7%) 
al linaje Asia-Americano; 10 (83%) de las muestras positivas para PVH58 se agruparon 
con el sublinaje A2, 1 (8%) perteneció al sublinaje A3 y 1 (8%) al linaje C. Los resultados 
de este estudio podrían advertir un potencial impacto menor en la reducción de cáncer 
cervical del uso de las vacunas contra PVH disponibles en el Ecuador. 
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ABSTRACT 
 
 
Human Papillomavirus (HPV) is the most common sexually transmitted infection 
worldwide which can cause intraepithelial neoplasias and cancer in cervix and anogenital 
areas. The detection of HPV types distribution among cancer lesions is necessary in order 
to analyze the potential impact of the available vaccines and the implementation of 
prophylactic and screening strategies. The identification of HPV molecular variants is a 
powerful tool for revealing epidemiologic and phylogenetic information about circulating 
HPV genomes in a specific area. However, in Ecuador there is limited information about 
HPV types in cancerous lesions and there is even more limited data about genome 
variants. The goal of this study was to characterize the HPV types responsible for 
malignancies associated with the genital tract in Ecuadorian women attending a major 
hospital in Quito. HPV was genotyped by the 21 HPV GenoArray Diagnostic Kit. A total 
of 167 cancerous and precancerous samples were analyzed and an 86% were HPV 
positive. The most common types were HPV16 (42%) and HPV58 (31%) in all grade 
lesions. HPV18 was found only in four samples (2.40%). Samples positive to HPV16 and 
HPV58 were further analyzed by amplifying and sequencing E6 and L1 genes. These 
analyses indicated that 14 (93%) of the HPV16 detected belonged to the European lineage 
and only 1 (7%) to Asian-American lineage; 10 (83%) of HPV58 grouped in A2 sub- 
lineage, 1 (8%) belonged to A3 and 1 (8%) to lineage C. Results of this study may inform 
about the potential lower impact on reducing cervical cancer of the bivalent and 
tetravalent HPV vaccines currently in use in Ecuador. 
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INTRODUCTION 
 
 
Background 
 
Papillomaviruses are double-stranded DNA viruses that belong to Papillomaviridae 
family 1, classified in 29 genera 2. Papillomavirus (PV) genomes have been found in 
humans (120 types), reptiles (2 types), birds (3 types), marsupials and other mammals (64 
types) 2 suggesting that PV evolutionary history goes back to 300 million years ago 3. 
Evolution on this family has been mainly based on mutations, deletions and insertions 
and not on recombination, consequently variations have not a genetic distance correlation 
3 4. The mutation rate on PV genomes is related to the host genome rate they infect since 
the virus uses its host machinery for replication 4. Lineage fixation is the term used to 
describe PV speciation and describes how multiple SNPs (single nucleotide 
polymorphisms) and indels (insertions and deletions) become fixed within papillomavirus 
lineages. The amount of these variations over time leads to speciation 3. When nucleotide 
divergence between  genomes is 10% or more,  2-10%, and  less than 2%, they are 
considered to be different types, subtypes, and variants, respectively 3 5. There are more 
than 160 types capable of infecting humans 6 that belong to different genus. However, 
alpha-papillomavirus comprise PV types that infect mucosal and cutaneous lesions in 
humans and primates with unique pathogenic activity 5. 
 
HPV and cancer 
 
More than 40 types are grouped in the alpha genus which can infect mucosal tissue in the 
anogenital area 3 7 and are involved in benign and malignant outcomes. These types can 
be grouped according to its levels of association with the progression of cancer. “Low 
risk” (LR) HPV types are 6, 11, 42, 43, 44 and 81 among others 8 and are generally 
associated to condyloma acuminate, respiratory papillomatosis and low-grade cervical 
intraepithelial lesions. They are rarely found on high-grade lesions 7. However, “high- 
risk” (HR) types are causative of squamous and glandular high-grade intraepithelial 
lesions and cancer 9 6 including cervical (100% of association between HPV and lesion), 
anal (90%), vulvar (40%), vaginal (40%), penile (40%) and oropharyngeal cancer (12%) 
7. HR HPV types are 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66 and 68 among 
 
others 8.  
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Cervical cancer is the fourth cause of female cancer deaths worldwide 10, while in Latin 
American it is the second 11 and in Ecuador it reaches the first most important type of 
cancer mortality in women of all ages 12. It is noteworthy that HPV is essential but not 
sufficient to cause cancer. The infection may be affected by host and viral genome 
variations, the host immune system and environmental factors 3. HPV16 and HPV18 are 
the two most prevalent types among women with cervical lesions around the world 
accounting for 70% of cases 7. However, in high-grade lesions HPV16-related types (such 
as HPV31, 52, 58, 33) are more important, especially in less developed countries where 
HPV58 is the second most frequent type while HPV18 ranks in fourth place 10 (Fig. 1). 
 
HPV Biology 
 
Human Papillomavirus (HPV) is a circular, non-enveloped, double stranded DNA virus 
that codifies 6 early expression genes (E1, E2, E4, E5, E6 and E7), protected by an 
icosahedral capsid composed of L1 (major capsid protein) and L2 (minor capsid protein) 
9 (Fig 2). Early genes codify non-structural proteins responsible for viral functions. E1 
works as a DNA depending ATPase and ATP depending helicase to regulate viral 
replication and transcription. E2 mediates episomal DNA dispersal during cell division. 
Protein E4 associates and destabilizes cytokeratins networks allowing koilocytes 
formation 
13
. It is also believed that regulates viral cycle by modulating host cell division 
cycle 
14
.  Protein E5 joins to membrane proteins, like growth factor receptors, and 
mediates cell transformation 
13
. E5 can also prevent apoptosis resulting from DNA 
damage 
1
. However, it is noteworthy that a part of E5 is deleted when the episomal viral 
genome becomes integrated 
1
. E6 and E7, known as oncogenes, are the most important 
genes that affect cell proliferation 
13
 by blocking the activity of tumor suppressors 
1
. E6 
joins to and marks P53 protein and promotes its degradation, thus resulting in apoptosis 
resistance and chromosomal instability. E6 is also capable of activating a catalytic 
subunit of telomerase, which is important for cellular immortalization. E7, however, 
inactivates Rb protein and also induce centriole amplification causing aneuploidy that 
contributes to carcinogenicity 
1
. 
 
Infection 
 
HPV requires epidermal or mucosal proliferative epithelial cells in order to establish an 
infection 1  6. Viral gene expression is suppressed in these cells causing a greater and 
lateral proliferation of infected cells 1. About 91% of infections are naturally cleared by 
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the immune system within two years 7  9  but in rare cases the infection persists during 
decades causing different grades of intraepithelial lesions and cancer 7, even though most 
low-grade lesions may regress spontaneously 6 by humoral and cellular immune 
responses against viral infections 1. Certain modifications of cellular genes affecting 
antigen presentation or the inability to successfully suppress viral oncogene transcription 
or functioning may cause persistent HPV infections, which is the most important risk 
factor for developing cancer 1. 
 
Besides high-risk HPV and viral load, there are other factors that contribute to malignancy 
1. Viral genome integration seems to play an important role in HPV pathogenesis. In high 
grade lesions, viral genome becomes integrated, deleting part of gene E2, which regulates 
viral gene transcription, and causing a greater E6 and E7 expression and viral 
proliferation; while in low grade lesions, viral genome stays in episomal form and E2 
protein remains intact 15. However, not all cancers have HPV genome integrated and it 
has been found integration of viral genome in HPV infections with normal cytology 16. 
 
Co-infections 
 
Multiple HPV types infections are very common, especially in women with no 
cytological abnormalities 17 18. Presence of one HPV type is associated to a higher risk of 
acquiring other HPV types 17, since it is the most common sexually transmitted virus. 
However, Thomas et al in their study suggested that there is no more likelihood of 
acquiring two specific HPV types than any other two types 19. It was previously thought 
that a co-infection may represent an increased risk for cancer but now there is evidence 
that the risk for persistence or cancer is independent of multiple types presence 17 18. 
 
Epidemiology 
 
Some authors have proposed that complex interactions between HPV types and HLA 
haplotypes may explain the differences in circulating HPVs in different regions of the 
world 20. For example, some countries show a low frequency of HPV18 and it may be 
because this HPV type seems to be uncommon in South America (only 5% of HPV 
infections) 20   and HPV18 has been detected in 5.68% of HPV positive samples in 
Ecuadorian women (unpublished data). Whereas in some regions in Asia21 22, México23, 
Nicaragua 24 and Brazil 25 show a high frequency of HPV58 in lesions of all grades. 
 
13 
 
With specific viral geographic dispersion and human closely evolution over time, HPV 
types have evolved into variant lineages and sub-lineages (1.5-10% and 0.5-1.4% of 
nucleotide divergence, respectively), with different association to higher risk of persistent 
infections and progression to cancer 4 26. HPV16 variants may vary in risk but they are all 
carcinogenic, while some HPV types with moderate oncogenic activity (such as 31, 52, 
56 or 58) may be a mixture of strongly carcinogenic lineages and variants with very weak 
carcinogenicity 26. Furthermore, for some types, like HPV16 and HPV18, variants are 
associated to specific geographical locations and even to ethnic populations but for other 
types this association is not well established 3. 
 
HPV16 variants are probably the best studied and characterized. One the first studies to 
be published in 1993 suggests that principal human races, such as Africans, Caucasians 
and East Asians, coevolved with papillomaviruses and it seems that various events of 
viral speciation took place in Africa. This research was the first study to establish a 
specific geographic distribution for HPV 16 and HPV18 variants 27. One point to consider 
is that the authors calculated the HPV18 mutation rate and they suggested that it would 
be an approximation of that for HPV16 27. However, in latter studies, it was confirmed 
that mutation rate in HPV does not have a correlation with genetic distance 1 3. There are 
4 lineages (A, B, C and  D) and 9 sub-lineages (A1-A4/B1-B2/D1-D3) 3 with a specific 
geographic distribution. Lineage A is known as the European branch, sublineage A2 is 
termed specifically as German variants and A4 as East Asians. African variants belong to 
lineage B and C. Sub-lineage D1 are termed as North American variants while D2 and 
D3 as Asian-Americans 3. The association of variants and its geographic location is 
relevant because Non-European HPV16 sub-lineages (especially Asian-American 
variants) tend to be more persistent 28, more aggressive and more carcinogenic than 
European counterparts 3 4. Greater carcinogenicity may be associated to more efficient 
viral replication (higher copy number per cell), and greater p53 degradation by E6 protein 
of this specific variants 29 (Fig 3). 
 
Little is known about HPV58 molecular variants around the world except for one study 
done in Asia with collaboration from 15 countries where the distribution worldwide of 
401 isolates was assessed. They also established the identification of HPV58 lineages and 
sub-lineages 30. HPV58 variants are classified in 4 lineages (A, B, C and D) and 7 sub- 
lineages (A1-A3/B1-B2/D1-D2) 4, but the evolutionary and pathological traits of all 
14 
 
variants require further study. Despite the lack of epidemiological information outside 
Asia, it is known that sub-lineage A2 seems to be the oldest lineage and probably 
disseminated with the early human migration into different parts of the world before other 
lineages emerged. This is because A2 was found in Africa, Asia, America and Europe 
while lineage D was not found in Asia and sub-lineage A1 was not detected in America 
30. About sub-lineage A3, two substitutions have been found to be associated to a higher 
risk of cancer: E7 T20I, which is located near RB protein joining domain, causes greater 
association to this protein, and E7 G35S, where a glycine is changed to serine, creates an 
additional phosphorylation site which may increase oncogenic activity 21 (Fig 4). 
 
HPV distribution related specifically to cancer in Ecuador is not well defined 12. However, 
there are some publications about HPV in anogenital samples 31 and cervical dysplasia 32 
in Ecuadorian women.  A  pilot  study published  in  2008,  worthy  to  be  mentioned, 
genotyped  HPV  in  71  chronic  cervicitis  and  pre-cancerous samples  and  its  results 
suggested that HPV16 (64.5%) and HPV81 (29%) were the most frequently found, 
followed by HPV31, 53, 56 and 58. Besides, the authors also showed that 85% of HPV16 
variants were European and 15% belonged to African-1 sub-lineage. No Asian- 
Americans or North Americans were found 33. Despite the information given by the 
authors, Ecuadorian studies about HPV types on cancerous lesions are not available. 
 
Prophylactic measures 
 
In an effort to prevent 70% of cervical cancers worldwide, two vaccines target the most 
common HPV types (HPV16 and 18). Gardasil, a quadrivalent recombinant vaccine, 
developed by Merck, with HPV6, 11, 16 and 18 VLPs (virus like particles) and Cervarix, 
a bivalent recombinant vaccine, produced by GlaxoSmithKline, with HPV16 and 18 
VLPs 7. Both prophylactic vaccines work in a three-dose regimen, however, one dose 
could be as protective and effective as three doses 34. 
 
According to WHO, at the end of 2012, 45 countries had implemented HPV vaccination 
programs 11, while in Ecuador it was introduced early this year on the Public Vaccination 
Program 35 for 9 to 11 years old girls in a two-dose regimen. Nevertheless, there is a nona- 
valent vaccine, produced by Merck, which is waiting to be approved in United States. 
The introduction of a nona-valent vaccine may reduce the combined incidence of high 
15 
 
grade lesions in cervical/vulvar/vaginal disease (caused by genotypes 6, 11, 16, 18, 31, 
33, 45, 52 and 58) in 96.7% 36. 
 
The detection of HPV types distribution among cancer lesions is important in order to 
analyze the potential impact of the available vaccines and to include more types in future 
prophylactic measures and screening methodologies. In this study, the distribution of 21 
HPV types among pre-cancerous, including CIN II (Cervical Intraepithelial Neoplasia) 
and CIN III, and cancerous (in situ and invasive) lesions in Ecuadorian women were 
evaluated. The presence of lineages and sub-lineages from the two most frequent HPV 
types in mono-infection samples was also analyzed. 
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Figure 1. Most frequent HPV types among women with normal cytology and cervical lesions worldwide 
compared to developing and developed countries (Bruni et al. 2014) 
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Figure 2. Circular and integrated HPV DNA organization (zur Hausen 
2002). 
 
 
 
 
 
 
 
 
 
Figure 3. HPV16 lineages and sublineages classification (Burk, Harari, and Chen 
2013) 
 
 
Figure 4. HPV58 lineages and sublineages classification (Chen et al. 2011) 
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ABSTRACT 18 
Human Papillomavirus (HPV) is the most common sexually transmitted infection 19 
worldwide which can cause intraepithelial neoplasias and cancer in cervix and 20 
anogenital areas. The detection of HPV types among cancer lesions is necessary to 21 
analyze the potential impact of the available vaccines and the implementation of 22 
prophylactic and screening strategies. The identification of HPV molecular variants is a 23 
powerful tool for revealing epidemiologic and phylogenetic information about 24 
circulating HPV genomes in specific areas. However, in Ecuador there is limited 25 
information about HPV types in cancerous lesions and there is even more limited data 26 
about variants. This study's goal was to characterize HPV types responsible for 27 
malignancies associated with the genital tract in Ecuadorian women attending a major 28 
hospital in Quito. HPV was genotyped by the 21 HPV GenoArray Diagnostic Kit. A 29 
total of 167 cancerous and precancerous samples were analyzed and an 86% were HPV 30 
positive. The most common types were HPV16 (42%) and HPV58 (31%) in all grade 31 
lesions. HPV18 was found in four samples (2.40%). Samples positive to HPV16 and 32 
HPV58 were further analyzed by sequencing E6 and L1 genes. These analyses indicated 33 
that 14 (93%) of the HPV16 detected belonged to European lineage and only 1 (7%) to 34 
Asian-American lineage; 10 (83%) of HPV58 grouped in A2 sub-lineage, 1 (8%) 35 
belonged to A3 and 1 (8%) to lineage C. Results of this study may inform about the 36 
potential lower impact on reducing cervical cancer of the bivalent and tetravalent HPV 37 
vaccines currently in use in Ecuador. 38 
39 
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INTRODUCTION 43 
Human papillomavirus is responsible for 98% of cervical cancer cases [Khan et al. 44 
2005] which is the fourth most important cause of cancer associated deaths in women 45 
worldwide [Bruni et al. 2014b]; in Ecuador it is the first cause of cancer deaths in 46 
women of all ages [Bruni et al. 2014a]. Human Papillomavirus (HPV) is a circular, non-47 
enveloped, double stranded DNA virus, protected by an icosahedral protein capsid 48 
[WHO 2010], which belongs to Papillomaviridae family. Approximately 40 types 49 
(classified in the Alphapapillomavirus genus) can infect mucosal tissue in the anogenital 50 
area [Dunne and Markowitz 2006] and show different levels of association to cancer. 51 
Viral types known as “low risk” (LR) cause condyloma acuminate, respiratory 52 
papillomatosis and low-grade cervical intraepithelial lesions; those classified as “high-53 
risk” (HR) can cause squamous and glandular high-grade intraepithelial lesions and 54 
cancer (cervical, anal, vulvar, vaginal, penile and oropharyngeal) [WHO 2010; Dunne 55 
and Markowitz 2006; Jong 2004]. However, 90% of high-risk HPV infections are 56 
cleared within two years by host immune responses [WHO 2010; Dunne and Markowitz 57 
2006]. Types HPV16 and HPV18 are the two most commonly associated to cancerous 58 
lesions in cervix around the world (70% of cases) [Dunne and Markowitz 2006] and 59 
these types are covered by the vaccines used in many countries including Ecuador 60 
[WHO 2013; MSP 2014b]. 61 
Identification of genome variants could be very informative about epidemiology and 62 
phylogenetics on HPV and about the spread of the virus in specific areas. High risk 63 
HPV types have diverged into lineages and sub-lineages (1.5-10% and 0.5-1.4% of 64 
nucleotide divergence, respectively) displaying different levels of carcinogenicity [Z. 65 
Chen et al. 2011; Schiffman et al. 2010]. Besides, variants of HPV16 and HPV18, are 66 
associated to specific geographical locations and even to ethnic populations. 67 
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In this study, 167 pre-cancerous and cancerous lesions from Ecuadorian women were 68 
analyzed in order to determine types, lineages and sublineages of HPV associated with 69 
this pathology. 70 
71 
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MATERIALS AND METHODS 72 
Clinical samples 73 
Pre-cancerous and cancer biopsies were obtained from all patients attending to 74 
colposcopy consulting in SOLCA Hospital in Quito (reference oncologic hospital 75 
that receives patients from different regions of Ecuador) from October to December 76 
2011 and from May 2012 to June 2013. Informed consent was obtained from all the 77 
participants, and the study was approved by the bio-ethics Committee of the 78 
Universidad San Francisco de Quito (USFQ) and the Teaching Department of SOLCA 79 
Hospital. Pathological tissue was collected by biopsy and split in two parts; one part 80 
was sent to SOLCA´s histopathology laboratory and another was preserved in 70% 81 
ethanol at -20°C for further processing. All of samples with high grade intraepithelial 82 
neoplasia (CIN II and CIN III) were included and subjected to DNA extraction. 83 
DNA extraction 84 
Total DNA was isolated by CTAB method described elsewhere [Saghai-Maroof et al. 85 
1984] with some modifications. Biopsies on 75% ethanol were washed twice in 1X PBS 86 
(137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4.7H2O, 1.4 mM KH2PO4, pH 7). Each 87 
sample was split in half, one part was kept in a freezer at -20ºC and the other was cut 88 
into small pieces with a sterile scalpel and digested with 20 µl proteinase K (20 mg/ml) 89 
in 700 µl CTAB solution (2% CTAB weight/vol, 1.4 mM NaCl, 20 mM EDTA pH 8, 90 
100 mM HCl pH 8) for 2 hours at 65°C with occasional mixing by inverting the 1.5 ml 91 
tubes. Chloroform/isoamyl alcohol (24:1 vol/vol) (700 µl) was added and the solution 92 
was vigorously mixed to form an emulsion that was centrifuged at 13, 300 x g for 5 min 93 
at room temperature. The aqueous phase (500 µl) was removed to a new tube with 1 ml 94 
of ethanol 100%, mixed by three-to-five inversions and kept at -20°C overnight. After a 95 
centrifugation step at 16, 110 x g for 10 min, the supernatant was discarded followed by 96 
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a washing step with 1 ml of 70% ethanol and centrifugation at 16, 110 x g for 10 min 97 
again. The supernatant was discarded and the tubes were dried at room temperature for 98 
20 to 30 min. Finally, DNA pellet was re-suspended in 50 µl of TE buffer (10 mM Tris-99 
HCl pH 8, 0.1 mM EDTA) and kept at -20°C for further processing. 100 
HPV genotyping 101 
The samples (1µl of total DNA) were genotyped by the 21 HPV GenoArray Diagnostic 102 
Kit (Hybribio Limited, Hong Kong, China) according to the manufacturer’s 103 
instructions. The Hybribio’s technique is based on E6 amplification and subsequent 104 
flow-through hybridization with specific probes within a membrane to identify 21 alpha 105 
HPV genotypes: 6, 11, 42, 43, 44 and 81 (low risk) and 16, 18, 31, 33, 35, 39, 45, 51, 106 
52, 53, 56, 58, 59, 66, 68 (high risk). 107 
Molecular analysis 108 
Genes E6 and L1 from the HPV16 and HPV58 mono-infected samples were amplified 109 
using a PCR protocol described elsewhere [Sotlar et al. 2004] with some modifications. 110 
In brief, E6 PCRs were carried out in a final volume of 30µl containing 1X colorless 111 
reaction buffer, 1.6mM MgCl2, 0.2µM of each dNTP, 0.26µM of primers GP-E6-3F and 112 
GP-E6-5B, 0.75U of GoTaq DNA Polymerase (PROMEGA Corporation, Madison, 113 
USA) and 250ng of DNA. The conditions for the amplification of a 630-bp product 114 
were an initial denaturation at 94°C for 4 min, followed by 40 cycles of 94°C for 1 min, 115 
40°C for 1 min, and 72°C for 2 min. The last cycle was followed by an elongation step 116 
at 72°C for 10 min. PCRs for L1 gene were performed in a final volume of 30µl 117 
containing 1X colorless reaction buffer, 2.5mM MgCl2, 200µM of each dNTP, 0.1µM 118 
of primers MY09 and MY11, 2 U of GoTaq DNA Polymerase (PROMEGA 119 
Corporation, Madison, USA) and 150 ng of DNA for the amplification of a 450-bp 120 
product. The amplification program was performed with an initial denaturation at 94°C 121 
John Wiley & Sons
Journal of Medical Virology
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
28
For Peer Review
8 
 
for 3 min followed by 40 cycles of 1-min denaturation at 94°C, 1-min annealing at 122 
55°C, and 1-min elongation at 72°C. The final extension step was done at 72°C for 10 123 
min. 124 
Genes E6 and L1 from samples infected with HPV16 (n=16) and HPV58 (n=12) were 125 
amplified, sequenced in Functional Biosciences (http://functionalbio.com/web/), and 126 
nucleotide sequences were concatenated. Each gene nucleotide sequence was aligned 127 
independently with references variants of HPV16 and HPV58 obtained from the NCBI 128 
GenBank using MEGA software version 6.0. The E6 and L1 genes independent 129 
alignments were concatenated manually for each strain. The phylogenetic trees, with a 130 
bootstrap analysis for 1000 replicates, were constructed by the maximum-likelihood 131 
algorithm using the same software. 132 
133 
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RESULTS 134 
A total of 167 fresh cervical and vaginal biopsies were included in the study. The 135 
patients´ ages ranged from 19 to 77 years old. The lesions were divided in three groups 136 
according to their histopathological results: 47 samples (28%) with CIN II (Cervical 137 
Intraepithelial Neoplasia type II), 62 samples (37%) with CIN III and 58 samples (35%) 138 
with either cervical, or vaginal cancer (in situ or invasive) (Table 1). Out the 167 139 
samples, 144 (86%) were positive for at least one of the HPV types screened; 35 out of 140 
47 (74%) CIN II lesions, 55 of 62 (89%) CIN III lesions and 54 of 58 (93%) cancerous 141 
lesions were positive for HPV infection. From the total of samples analyzed, 59% were 142 
infected with only one HPV type and 27% had multiple infections with two or three 143 
types and 14% were negative for HPV DNA (data not shown). All co-infections had at 144 
least one high-risk HPV type, however, seven mono-infected samples had only low-risk 145 
types. HPV6 or HPV11 were detected in five samples showing CIN II and CIN III; 146 
HPV42 was identified in one CIN II lesion, and HPV43 in a patient with CIN III. No 147 
low-risk genotypes were detected in cancer lesions. 148 
The results of genotyping showed that 19 out of 21 HPV types tested were detected at 149 
least once. Overall, HPV16 and HPV58 were the most frequently detected in mono-150 
infections (61%, and 44%, respectively) and in co-infections (44%, and 42%, 151 
respectively) (data not shown). HPV16 was the most frequent genotype in both pre-152 
cancerous (CIN II and CIN III) and cancerous lesions, while HPV58 was detected in all 153 
grade lesions (Table 1), followed by HPV52, 6/11, 66 and 31 in decreasing frequency. 154 
Intriguingly, HPV18 was only detected in four samples (2%). 155 
Nucleotide sequences from HPV16 amplicons grouped mostly into the European branch 156 
(Lineage A) (Figure 1), and only one (sample 88M) clustered with the Asian-American 157 
variants (Sub-lineages D2/D3). Among sequences with high similarity to European 158 
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variants (Table 2), 20M was identical to A1 sub-lineage, while 14 sequences grouped 159 
into A2 sub-lineage and sample 69M clustered within lineage A but had one non-160 
synonymous substitution shared with lineages B, C and D. 161 
Regarding HPV58 amplicons, 10 out of 12 sequences grouped into sub-lineage A2 162 
(Figure 2) but sequence from sample LM82 showed one synonymous substitution in 163 
common with sublineage A3, and amplicon from sample LM51 had one synonymous 164 
substitution and four non-synonymous substitutions present in lineage C sequences. No 165 
samples aligned with sub-lineage A1, lineages B or D (Table 3). 166 
167 
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DISCUSSION 168 
This study is the first report of HPV type distribution and assessment on HPV58 169 
variants among Ecuadorian women diagnosed with pre-cancer and cancerous lesions 170 
contributing to the understanding of HPV epidemiology in Ecuador. Two types HPV16 171 
(61% in mono-infections and 44% in co-infections) and HPV58 (44% and 42%, 172 
respectively) were associated to pre-cancerous and cancerous lesions from Ecuadorian 173 
women attending to a major hospital in Quito. It was surprising to find high percentage 174 
of pre-cancerous and cancerous lesions associated to HPV58, although similar results 175 
have been described in Asia [Huang et al. 1997; C.-A. Chen et al. 2006], México 176 
[González-Losa et al. 2004; Piña-Sánchez et al. 2006], Nicaragua [Hindryckx 2006] and 177 
Brazil [Fernandes et al. 2013]. On the other hand, it was also unexpected to find very 178 
little (2.4%) of HPV18 associated to pre-cancerous and cancerous lesions; however, 179 
similar results have been described previously in Ecuador [Tornesello et al. 2008], 180 
Nicaragua [Hindryckx 2006] and Mexico [Piña-Sánchez et al. 2006]. This low 181 
frequency of HPV18 found in this study may be because this HPV type seems to be 182 
uncommon in South America (only 5% of HPV infections) as opposed to 11% in North 183 
America and 8% in Europe [Clifford 2005]. HPV18 has been detected in 5% of HPV 184 
positive samples in Ecuadorian women (data not shown). Some authors have proposed 185 
that complex interactions between HPV types and HLA haplotypes may explain the 186 
differences in circulating HPVs in different regions of the world [Clifford 2005]. 187 
In addition, a 27% of samples were infected with two or three HPV types. HPV6/11 188 
were detected in cancer but always in co-infections with at least one HR HPV, which is 189 
in accordance to previously published results; no clear association between specific 190 
HPV combinations was observed as previously described in other reports [zur Hausen 191 
2002; Thomas et al. 2000]. Seven pre-cancerous lesions (but no cancerous lesions) were 192 
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associated to infections with low risk HPV types, this finding also concurs with 193 
previous reports [zur Hausen 2002]. 194 
Nucleotide sequences of HPV16 variants clustered mainly with the European linage, 195 
most of them belonged to A2 sub-lineage (German branch), one sequence clustered with 196 
A1 sub-lineage (European lineage); and one sequence seemed to belong to the D2 sub-197 
lineage, known as Asian-American 2 branch (figure 1). Some reports from other Latin-198 
Americans countries have also described that most HPV16 variants are European 199 
[Schiffman et al. 2010; Villa et al. 2000; Sichero et al. 2007; Hildesheim et al. 2001; 200 
Picconi et al. 2003]. However, one study from Mexico found that 23.8% HPV16 201 
variants belonged to European lineages and 23.2% to Asian-American sub-lineages 202 
[Berumen et al. 2001]. This is relevant because Non-European HPV16 sublineages 203 
(especially the Asian-American) tend to be more persistent [Villa et al. 2000], more 204 
aggressive and more carcinogenic than European counterparts [Burk, Harari, and Chen 205 
2013; Z. Chen et al. 2011; Berumen et al. 2001; Sichero et al. 2007; Hildesheim et al. 206 
2001]. Greater carcinogenicity may be associated to more efficient viral replication 207 
(higher copy number per cell), and greater p53 degradation by E6 protein [Berumen et 208 
al. 2001]. 209 
The phylogenetic analysis of Ecuadorian HPV58 sequences showed that most variants 210 
belonged to the A2 sub-lineages which may be the oldest HPV58 sub-lineage and from 211 
which the other lineages emerged [P. K. S. Chan et al. 2011]. One amplicon sequence 212 
clustered with sub-lineage A3; two substitutions found in the latter sequence have been 213 
associated previously to higher risk of cancer: E7 T20I causes greater affinity to the RB 214 
protein and E7 G35S creates an additional phosphorylation site which may increase 215 
oncogenic activity [Paul K. S. Chan et al. 2002]. 216 
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Assessment of the oncogenic HPV types affecting Ecuadorian women is vital to analyze 217 
the possible impact of the vaccination program in our population. Since the bivalent 218 
HPV vaccine was introduced in Ecuador early 2014 [MSP 2014a], even though both 219 
vaccines, bivalent and tetravalent, have been available for more than 4 years; our results 220 
may advised less efficacy on reducing cancer in Ecuadorian women. The results 221 
presented here may suggest that this vaccine will be less efficacious in Ecuador than in 222 
other countries were HPV16 and HPV18 are the main causes of cervical cancer. 223 
Additionally it would be important to monitor mutations in capsid and oncogenic 224 
proteins for they will inform about predicted oncogenicity and vaccination success 225 
[Berumen et al. 2001]. The introduction of a nona-valent vaccine may reduce the 226 
combined incidence of high grade lesions in cervical/vulvar/vaginal disease (caused by 227 
genotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58) in 96.7% [Eisele et al. 2013]. 228 
As the number of some variants is very small, it is hard to compare each variant 229 
category and it does not allow additional analysis. Nevertheless, as the study focuses 230 
only on pre-cancer and cancer, its results are of great interest to understand better the 231 
epidemiology and frequency of HPVs present in Ecuador. Moreover, the samples 232 
analyzed came from an nationwide oncologic referral center which may allow us to 233 
infer that similar results will be found in patients form different regions of Ecuador. It is 234 
also noteworthy that this study probably is the first report of HPV58 molecular variants 235 
done outside Asia. Pathological characteristics of HPV 58 variants and its associations 236 
with cancer needs further studies. 237 
238 
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Table 1. Most frequent HPV types (mono- and co-infections) found in precancerous and cancerous 
lesions in Ecuadorian women attending a large hospital in Quito. CIN: Cervical Intraepithelial Neoplasia.  
* Cancer biopsies include cervical and vaginal samples (n=167). Some samples had more than one HPV 
type 
  n HPV+  (%) HPV16  (%) HPV58  (%) HPV52  (%) Others  (%) 
CIN II 47 35  (74) 13  (37) 7  (20) 5  (14) 23  (66) 
CIN III 62 55  (89) 24  (44) 20  (36) 5  (9) 27  (49) 
Cancer * 58 54  (93) 24  (44) 17  (31) 7  (13) 26  (48) 
Total 167 144  (86) 61  (42) 44  (31) 17  (12) 76  (53) 
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Figure 1. Maximum-likelihood tree using nucleotide sequences of E6 and L1 genes from HPV16 variants 
obtained in this study. Histopathology diagnosis are denoted as CIN (cervical intraepithelial neoplasia) II, 
CIN III and cancer. The rest of the sequences were obtained from GenBank. Numbers indicate bootstrap 
values from 1000 pseudo-replicates. Representative genomes for HPV16 lineages (termed A, B, C and D) 
and sub-lineages (termed A1-A4/B1-B2/D1-D3) were used as variant references [Burk, Harari, and Chen 
2013].  Regional variants are indicated as:  E, European variant; As, East Asian; Afr, African; NA, North 
American; AA, Asian-American.  
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Figure 2. Maximum-likelihood tree using nucleotide sequences of E6 and L1 genes from HPV18 variants 
obtained in this study. Histopathology diagnosis of the sequences reported here are denoted as CIN (cervical 
intraepithelial neoplasia) II, CIN III and cancer. The rest of the sequences were obtained from GenBank. 
Numbers indicate bootstrap values from 1000 pseudo-replicates. Representative genomes for HPV58 
lineages (termed A, B, C and D) and sub-lineages (termed A1-A3/B1-B2/D1-D2) were used as variant 
references [Z. Chen et al. 2011].    
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